Gilead has shared new results from its ARTISTRY-1 and ARTISTRY-2 trials, which looked at how well a new combination of medicines works in adults with HIV who are already being successfully treated. The results were presented at a major medical conference in 2026. The trials found that switching to a combination of bictegravir and lenacapavir kept the virus under control just as well as other treatments. This new combination was also found to be as effective as a commonly used HIV medicine called Biktarvy. The results from ARTISTRY-1 were also shared in a talk and published in a well-known medical journal, The Lancet. Gilead said that while single-tablet HIV treatments have greatly improved the lives of many people with HIV, some people can’t take these because of resistance to the virus, side effects, or other health issues. This means there’s a need for new treatment options that better suit people’s needs. The ARTISTRY trials show that the combination of bictegravir and lenacapavir could be a good new option for people with HIV who are already doing well on their current treatment. At 48 weeks, very few people in the trials had a detectable amount of the virus in their blood, and the new combination was generally well tolerated with no new safety concerns. Gilead plans to share these results with health authorities soon. However, it’s important to note that this combination of medicines is still being studied and is not yet approved anywhere in the world.